Interestingly, the proportion of phased loci sharing the miR2118 recognition site was significantly higher (p-value = 1.5 × 10−08) in the differentially expressed group (i.e. higher expression in O. barthii) (61%%, n = 854) than in the group of non-differentially expressed phased loci (16 %, n = 38) (Additional file 6).
B adults feeding on virus-infected plants had a significantly lower proportion of phase I oocytes but significant higher proportions of phase II, III, and IV oocytes, compared to the B adults feeding on healthy plants (Table 1; Figure 3).
The proportion of phase II facets are similar in all the modern hunter-gatherer groups with the exception of the Khoe-San in which phase II areas are less developed.
The proportion of phase II facets are similar in all the modern hunter-gatherer groups (between 30 % and 33) with the exception of the Khoe-San in which phase II areas are less than 25%.
This hypothesis would predict that Mre11 is involved in the UNG dependent pathway, which is mainly responsible for generation of phase 1b mutations (G/C transversions) but, together with polymerase η (pol η), also generates a small proportion of phase II mutations (A/T mutations) [35].
The US conducts more trials in all phases of drug development but has a greater proportion of phase 3 trials.
There is a general trend toward an increasing proportion of phase-0 introns caused by gained introns.
In contrast to the prediction of introns-early, the inferred evolution of intron phase distribution showed that the proportion of phase-0 introns increased over evolution.
The percentage of G0/G1 phase in KIAA0101 positive cells is 64.38% ± 1.46, while in negative cells the proportion of phase G0/G1 is 54.7% ± 1.43.
The difference might be explained in part by the higher proportion of Phase I trials at SNUH compared to KUHP, as the content of informed consent is different between Phase I trial and trials that have moved further along.
Specific recommendations for GCC include: Enhanced Support for New Investigators: 1. Maintain and support the 'Rising Stars' award program, whereby a proportion of Phase I and II grants are designated for new investigators.
